Redpin Therapeutics

Redpin Therapeutics Overview

Founded 2017
Founded
Status Private
Latest Deal Type Series A
Latest Deal Amount $15.5M
Latest Deal Amount
Investors 6

Redpin Therapeutics General Information

Description

Operator of a biotechnology company intended to develop platform technologies for regulating cell activity. The company's services focus on neurological disorders for which its technology can have widespread implications and also facilitates targeted regulation of neuronal activity in the brain to achieve treatment and control of CNS circuits and other disorders, enabling clients to get targeted cell activation or inhibition controlled by low doses of the anti-smoking drug varenicline.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 101 Sixth Avenue
  • Third Floor
  • New York, NY 10013
  • United States
+1 (917) 000-0000

Redpin Therapeutics Timeline

201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Redpin Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 25-Mar-2020 $15.5M 0000 0000 Completed Generating Revenue
2. Accelerator/Incubator 21-Jun-2018 00.00 Completed Generating Revenue
1. Seed Round 29-Mar-2018 $1.5M $1.5M 000 Completed Generating Revenue

Redpin Therapeutics Cap Table

To view Redpin Therapeutics‘s complete cap table, request access >>
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.00

Redpin Therapeutics Executive Team (7)

Name Title Board Seat Contact Info
Elma Hawkins Ph.D Co-Founder, President, Chief Executive Officer & Board Member
David Bleakman Ph.D Chief Scientific Officer
Jeffrey Friedman Co-Founder
Jonathan Dordick Ph.D Co-Founder
Michael Kaplitt Ph.D Co-Founder

Redpin Therapeutics Board Members (2)

Name Representing Role Since
Dmitry Kuzmin Ph.D 4BIO Capital Partners Board Member 000 0000
Elma Hawkins Ph.D Redpin Therapeutics Co-Founder, President, Chief Executive Officer & Board Member 000 0000

Redpin Therapeutics Investors (6)

To view Redpin Therapeutics‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
4BIO Capital Partners Asset Manager Minority 000 0000 000000 0
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Arkin Holdings PE/Buyout Minority 000 0000 000000 0

Ready to get started?

Request a free trial